Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[Afatinib is an irreversible erythroblastosis oncogene B (ErbB) family blocker, able to inhibit the kinase domains of EGFR, HER2 and HER4, and the transphosphorylation of ErbB3 that has recently been approved in the United States for the first-line treatment of EGFR-mutated NSCLC and in Europe and Japan for the treatment of EGFR-mutated TKI-naive patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• assertion description "[Afatinib is an irreversible erythroblastosis oncogene B (ErbB) family blocker, able to inhibit the kinase domains of EGFR, HER2 and HER4, and the transphosphorylation of ErbB3 that has recently been approved in the United States for the first-line treatment of EGFR-mutated NSCLC and in Europe and Japan for the treatment of EGFR-mutated TKI-naive patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Afatinib is an irreversible erythroblastosis oncogene B (ErbB) family blocker, able to inhibit the kinase domains of EGFR, HER2 and HER4, and the transphosphorylation of ErbB3 that has recently been approved in the United States for the first-line treatment of EGFR-mutated NSCLC and in Europe and Japan for the treatment of EGFR-mutated TKI-naive patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Afatinib is an irreversible erythroblastosis oncogene B (ErbB) family blocker, able to inhibit the kinase domains of EGFR, HER2 and HER4, and the transphosphorylation of ErbB3 that has recently been approved in the United States for the first-line treatment of EGFR-mutated NSCLC and in Europe and Japan for the treatment of EGFR-mutated TKI-naive patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Afatinib is an irreversible erythroblastosis oncogene B (ErbB) family blocker, able to inhibit the kinase domains of EGFR, HER2 and HER4, and the transphosphorylation of ErbB3 that has recently been approved in the United States for the first-line treatment of EGFR-mutated NSCLC and in Europe and Japan for the treatment of EGFR-mutated TKI-naive patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Afatinib is an irreversible erythroblastosis oncogene B (ErbB) family blocker, able to inhibit the kinase domains of EGFR, HER2 and HER4, and the transphosphorylation of ErbB3 that has recently been approved in the United States for the first-line treatment of EGFR-mutated NSCLC and in Europe and Japan for the treatment of EGFR-mutated TKI-naive patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP380808.RARgTX-WwZuIU6tq0EWI6nD9rDZEBtjwQH1ITlfH4-bIc130_assertion description "[Afatinib is an irreversible erythroblastosis oncogene B (ErbB) family blocker, able to inhibit the kinase domains of EGFR, HER2 and HER4, and the transphosphorylation of ErbB3 that has recently been approved in the United States for the first-line treatment of EGFR-mutated NSCLC and in Europe and Japan for the treatment of EGFR-mutated TKI-naive patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP380808.RARgTX-WwZuIU6tq0EWI6nD9rDZEBtjwQH1ITlfH4-bIc130_provenance.
• NP1165369.RAVXflY2ntb6sCD6YLMBR5Qk-5ZzMX8y7zQ_uQRAg4ZvU130_assertion description "[Afatinib is an irreversible erythroblastosis oncogene B (ErbB) family blocker, able to inhibit the kinase domains of EGFR, HER2 and HER4, and the transphosphorylation of ErbB3 that has recently been approved in the United States for the first-line treatment of EGFR-mutated NSCLC and in Europe and Japan for the treatment of EGFR-mutated TKI-naive patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1165369.RAVXflY2ntb6sCD6YLMBR5Qk-5ZzMX8y7zQ_uQRAg4ZvU130_provenance.
• NP1165370.RAVhV_k-z7f_KkhxVrH0LGn0Nlrx0rUN4guPKtaMp38_Q130_assertion description "[Afatinib is an irreversible erythroblastosis oncogene B (ErbB) family blocker, able to inhibit the kinase domains of EGFR, HER2 and HER4, and the transphosphorylation of ErbB3 that has recently been approved in the United States for the first-line treatment of EGFR-mutated NSCLC and in Europe and Japan for the treatment of EGFR-mutated TKI-naive patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1165370.RAVhV_k-z7f_KkhxVrH0LGn0Nlrx0rUN4guPKtaMp38_Q130_provenance.
• NP1165373.RAWaotluSvl2IkSAap2l-3j87XHWgMAOBDPNdDAzfirCI130_assertion description "[Afatinib is an irreversible erythroblastosis oncogene B (ErbB) family blocker, able to inhibit the kinase domains of EGFR, HER2 and HER4, and the transphosphorylation of ErbB3 that has recently been approved in the United States for the first-line treatment of EGFR-mutated NSCLC and in Europe and Japan for the treatment of EGFR-mutated TKI-naive patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1165373.RAWaotluSvl2IkSAap2l-3j87XHWgMAOBDPNdDAzfirCI130_provenance.
• NP379561.RAgfstRM0xmtkpScFUCeIPBxUiHWhi9W2FL1dZ-UFThfk130_assertion description "[Afatinib is an irreversible erythroblastosis oncogene B (ErbB) family blocker, able to inhibit the kinase domains of EGFR, HER2 and HER4, and the transphosphorylation of ErbB3 that has recently been approved in the United States for the first-line treatment of EGFR-mutated NSCLC and in Europe and Japan for the treatment of EGFR-mutated TKI-naive patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP379561.RAgfstRM0xmtkpScFUCeIPBxUiHWhi9W2FL1dZ-UFThfk130_provenance.
• NP1165374.RArreZi1-GnRuxb7IbG98NsmNcjC0PzCP2jZTRnA8HWxM130_assertion description "[Afatinib is an irreversible erythroblastosis oncogene B (ErbB) family blocker, able to inhibit the kinase domains of EGFR, HER2 and HER4, and the transphosphorylation of ErbB3 that has recently been approved in the United States for the first-line treatment of EGFR-mutated NSCLC and in Europe and Japan for the treatment of EGFR-mutated TKI-naive patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1165374.RArreZi1-GnRuxb7IbG98NsmNcjC0PzCP2jZTRnA8HWxM130_provenance.
• NP380668.RA8wYFWv3dErmEwBTur06tCwKIj7Jso6dy9Ts21qpGZu8130_assertion description "[Afatinib is an irreversible erythroblastosis oncogene B (ErbB) family blocker, able to inhibit the kinase domains of EGFR, HER2 and HER4, and the transphosphorylation of ErbB3 that has recently been approved in the United States for the first-line treatment of EGFR-mutated NSCLC and in Europe and Japan for the treatment of EGFR-mutated TKI-naive patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP380668.RA8wYFWv3dErmEwBTur06tCwKIj7Jso6dy9Ts21qpGZu8130_provenance.
• NP381117.RA1TlQ0hYIYqpzenNtRbJu9P0slX7hLvxir1karmVGZpI130_assertion description "[Afatinib is an irreversible erythroblastosis oncogene B (ErbB) family blocker, able to inhibit the kinase domains of EGFR, HER2 and HER4, and the transphosphorylation of ErbB3 that has recently been approved in the United States for the first-line treatment of EGFR-mutated NSCLC and in Europe and Japan for the treatment of EGFR-mutated TKI-naive patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP381117.RA1TlQ0hYIYqpzenNtRbJu9P0slX7hLvxir1karmVGZpI130_provenance.
• NP369518.RAHZ5V_FdNc5Z8MOiu-Vt9mRC8t8QNnq9OLTSQNbzQEkU130_assertion description "[Afatinib is an irreversible erythroblastosis oncogene B (ErbB) family blocker, able to inhibit the kinase domains of EGFR, HER2 and HER4, and the transphosphorylation of ErbB3 that has recently been approved in the United States for the first-line treatment of EGFR-mutated NSCLC and in Europe and Japan for the treatment of EGFR-mutated TKI-naive patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP369518.RAHZ5V_FdNc5Z8MOiu-Vt9mRC8t8QNnq9OLTSQNbzQEkU130_provenance.
• NP1165372.RAwDmqvBscs2uPpYh3WXGX4_6Bj6MQr08hj-4hC_2Hri4130_assertion description "[Afatinib is an irreversible erythroblastosis oncogene B (ErbB) family blocker, able to inhibit the kinase domains of EGFR, HER2 and HER4, and the transphosphorylation of ErbB3 that has recently been approved in the United States for the first-line treatment of EGFR-mutated NSCLC and in Europe and Japan for the treatment of EGFR-mutated TKI-naive patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1165372.RAwDmqvBscs2uPpYh3WXGX4_6Bj6MQr08hj-4hC_2Hri4130_provenance.